Clinical trials: Depressive State
Major Depressive Disorder
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06963021
- Testing
- NBI-1065845
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Depression
The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder
This study evaluated the effectiveness and safety of improving depressive symptoms by applying tDCS for 6 weeks to patients with mild to moderate depression.
- Trial name
- NCT04720040
- Testing
- Mind STIM
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Ybrain Inc.
Study Adherence, Depressive Disorder
Message-Based Psychotherapy and Digital Treatment Sequences for Depression
This partnership between Talkspace and the University of Washington (UW) ALACRITY Center will determine how effective unlimited text-based psychotherapy for depression is when compared to once-a-week psychotherapy.
- Trial name
- NCT04513080
- Testing
- Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP), Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy
- Where
- United States
- Volunteers
- 1,184 people
- Sponsor
- Talkspace
Depression / Major Depressive Disorder, Anxiety
Activating Voice Journaling for Mental Health With Voice Biomarkers
This retrospective observational study evaluated the relationship between voice characteristics and self-reported mental health symptoms using longitudinal data collected through the Kintsugi Voice Journaling app.
- Trial name
- NCT07789808
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Anxiety Depression, Disability Physical
Exploratory Study for Toivoa-001 on Human Factors
The Study will evaluate Rauha as an experimental digital therapeutic for persons with Disabilities suffering from anxiety and/or depression.
- Trial name
- NCT06477913
- Testing
- Rauha
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Toivoa Inc
Depression
Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.
Phase III long-term safety study of Effexor XR in patients with major depression.
- Trial name
- NCT00225524
- Testing
- Effexor XR
- Where
- 73 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Treatment Resistant Major Depressive Disorder
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD).
- Trial name
- STRIDE-1 (NCT02741791)
- Testing
- AXS-05, Bupropion
- Where
- 74 sites in United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Depressive Symptoms, Anxiety Symptoms
Stabilizing Behavioral Rhythms to Improve Mental Health
In order to assess the efficacy of the Rhythm Stabilization component of HealthRhythms' product, investigators will recruit 128 outpatients between the ages of 18 and 65, presenting to the University of Utah Department of…
- Conditions
- Depressive Symptoms, Anxiety Symptoms, Sleep Symptoms
- Trial name
- SRMH (NCT03152864)
- Testing
- Full Package
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- HealthRhythms, Inc.
Major Depressive Disorder (MDD)
A Phase II Study to Evaluate NH102 for Depression
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine .
- Trial name
- NH102-21 (NCT06842992)
- Testing
- NH102, Duloxetine Hydrochloride Enteric-coated Capsule
- Where
- 24 sites in China
- Volunteers
- 243 people
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Major Depressive Disorder
A Study of MD-120 in Patients With Depression
The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.
- Trial name
- NCT04345471
- Testing
- Desvenlafaxine 100 mg, Desvenlafaxine 50 mg
- Where
- Japan
- Volunteers
- 615 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
- Trial name
- P-TRD (NCT03775200)
- Testing
- Psilocybin
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 233 people
- Sponsor
- COMPASS Pathways
Depression
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.
- Trial name
- NCT00864981
- Testing
- Bupropion HCI ER Tablets, 150 mg; EON Labs Inc., WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sandoz
Postpartum Depression
A Six-Month Prospective Follow-Up Study of WB001
This study is a 6-month follow-up study to WB001-001 conducted to assess and evaluate the durability of the effect of {WB001+TAU} beyond the 8-week treatment period.
- Trial name
- NCT05693792
- Testing
- Observational
- Sponsor
- Woebot Health
Post Surgical Respiratory Failure, Respiratory Complication
Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline With the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS)
Investigators will enroll 493 patients who will undergo non-cardiac surgery, receive supplemental oxygen via face mask or nasal cannula, and will be on continuous pulse oximetry monitor in the Post Anesthesia Care Unit (PACU).
- Conditions
- Post Surgical Respiratory Failure, Respiratory Complication, Opioid Induced Respiratory Depression, Respiratory Arrest
- Trial name
- NCT07793981
- Testing
- Linshom Continuous Predictive Respiratory Monitoring
- Where
- 2 sites in United States
- Volunteers
- 394 people
- Sponsor
- Linshom Medical, Inc.
Depression, Bipolar I Disorder
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- 3112 Ped BPD (NCT04777357)
- Testing
- Cariprazine
- Where
- 81 sites in United States, Puerto Rico and 1 more
- Volunteers
- 380 people
- Sponsor
- AbbVie
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Depression
Multiple Ascending Dose Study of NH102 in Healthy Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as multiple oral dose at escalating dose levels in healthy participants.
- Trial name
- NCT07324408
- Testing
- NH102
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Depression / Major Depressive Disorder, Depressed Mood
REM Sleep Disruption and Its Potential Uses in Depression Management
This randomized study evaluated whether brief wrist vibrations delivered through an Apple Watch during algorithm-identified rapid eye movement (REM) sleep could reduce depressive symptoms over approximately four weeks.
- Trial name
- NCT07891806
- Testing
- REM-Contingent Smartwatch Haptic Stimulation, Smartwatch Sleep Monitoring and Smart Alarm
- Where
- 2 sites in Romania
- Volunteers
- 208 people
- Sponsor
- WAKEZ HEALTH TECH ECOSYSTEM SRL
Depressive Disorder
rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure
This study is testing a process (rEEG)for selecting the most appropriate medication(s) to treat a patient's depression versus a control group being treated according to a standardized method, the modified Star*D Algorithm.
- Trial name
- NCT00437827
- Testing
- Star*D algorithm, rEEG-guided therapy
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- MYnd Analytics